Abschluss eines nicht exklusiven Rabattvertrages nach§ 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Atomoxetin (ATC-Code: N06BA09) innerhalb des Zeitraumes vom 01.10.2026 bis zum 30.09.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

TENDER DESCRIPTION

For the active ingredient Atomoxetine (ATC code: N06BA09), AOK Lower Saxony. The Health Insurance Fund offers rebate agreements to all interested pharmaceutical companies without a selection decision for the period until the entry into force of exclusive contracts following a formal award procedure according to the regulations of Part 4 of the GWB. Contract conclusions are made within the framework of an "open-house model" and serve as a bridge between the start of generic competition (patent expiry) and the awarding of exclusive contracts. The offered contracts are non-exclusive; contracts with all market participants (pharmaceutical companies) are desired by AOK Lower Saxony. In the open-house model, uniform conditions apply to all participants. Contract contents, conditions, and access procedures are uniform – individual negotiations are generally not conducted. Contract durations are a maximum of twenty-four months, the earliest contract start date is 01.10.2026. All contracts end no later than 30.09.2028, regardless of the date of the respective contract conclusion. Joining or concluding a contract can take place within the twenty-four-month period on the first day of each…

TENDER BRIEF

TENDER DOCUMENTS